Nucleophosmin is a highly and ubiquitously expressed protein, mainly localized in nucleoli but able to shuttle between nucleus and cytoplasm. Nucleophosmin plays crucial roles in ribosome maturation and export, centrosome duplication, cell cycle progression, histone assembly and response to a variety of stress stimuli. Much interest in this protein has arisen in the past ten years, since the discovery of heterozygous mutations in the terminal exon of the NPM1 gene, which are the most frequent genetic alteration in acute myeloid leukemia. Nucleophosmin is also frequently overexpressed in solid tumours and, in many cases, its overexpression correlates with mitotic index and metastatization. Therefore it is considered as a promising target for the treatment of both haematologic and solid malignancies. NPM1 targeting molecules may suppress different functions of the protein, interfere with its subcellular localization, with its oligomerization properties or drive its degradation. In the recent years, several such molecules have been described and here we review what is currently known about them, their interaction with nucleophosmin and the mechanistic basis of their toxicity. Collectively, these molecules exemplify a number of different strategies that can be adopted to target nucleophosmin and we summarize them at the end of the review.

Molecules that target nucleophosmin for cancer treatment: an update / DI MATTEO, Adele; Franceschini, M; Chiarella, Sara; Rocchio, Serena; TRAVAGLINI ALLOCATELLI, Carlo; Federici, L.. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7:28(2016), pp. 44821-44840. [10.18632/oncotarget.8599]

Molecules that target nucleophosmin for cancer treatment: an update

DI MATTEO, Adele
;
CHIARELLA, SARA;ROCCHIO, SERENA;TRAVAGLINI ALLOCATELLI, Carlo;
2016

Abstract

Nucleophosmin is a highly and ubiquitously expressed protein, mainly localized in nucleoli but able to shuttle between nucleus and cytoplasm. Nucleophosmin plays crucial roles in ribosome maturation and export, centrosome duplication, cell cycle progression, histone assembly and response to a variety of stress stimuli. Much interest in this protein has arisen in the past ten years, since the discovery of heterozygous mutations in the terminal exon of the NPM1 gene, which are the most frequent genetic alteration in acute myeloid leukemia. Nucleophosmin is also frequently overexpressed in solid tumours and, in many cases, its overexpression correlates with mitotic index and metastatization. Therefore it is considered as a promising target for the treatment of both haematologic and solid malignancies. NPM1 targeting molecules may suppress different functions of the protein, interfere with its subcellular localization, with its oligomerization properties or drive its degradation. In the recent years, several such molecules have been described and here we review what is currently known about them, their interaction with nucleophosmin and the mechanistic basis of their toxicity. Collectively, these molecules exemplify a number of different strategies that can be adopted to target nucleophosmin and we summarize them at the end of the review.
2016
B23; acute myeloid leukemia; nucleophosmin; solid tumours; targeted therapy
01 Pubblicazione su rivista::01a Articolo in rivista
Molecules that target nucleophosmin for cancer treatment: an update / DI MATTEO, Adele; Franceschini, M; Chiarella, Sara; Rocchio, Serena; TRAVAGLINI ALLOCATELLI, Carlo; Federici, L.. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7:28(2016), pp. 44821-44840. [10.18632/oncotarget.8599]
File allegati a questo prodotto
File Dimensione Formato  
Di Matteo_Molecules_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 3.88 MB
Formato Adobe PDF
3.88 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/867529
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 51
social impact